We Help Companies Find New Sales Opportunities
Oxford Biomedica has acquired Oxxon Therapeutics, the Oxford-based therapeutic vaccines company, for £16m.
Oxford Biomedica is planning to raise up to £30m in a share offer in order to fund international expansion and clinical trials for new gene therapy-based products.
Oxford Biomedica is seeking a partner to fund the development of its TroVax cancer vaccine, and is also planning to seek a listing on London's main market.
Oxford Biomedica has raised £8.5m in a share placing in order to set up a new gene division, and the proceeds will be spent on the recruitment of scientists and the marketing of two new technologies.
Oxford Biomedica has raised a further £5m in a share issue for the development of gene therapy, and is looking to move from the Alternative Investment Market to a full stockmarket listing.
Oxford Biomedica, the gene-therapy concern, is planning a public share offer in November in order to raise £5m for the funding of a lease on a site in Oxford and the recruitment of up to 30 staff.